SCHEMBL5835133

SCHEMBL5835133

COc1cc(Cl)c(S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2)cc1OC

nearest known ligand 0.84

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 14/20 0.84
MCHR1 Q99705 1/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
ERBB2 P04626 1/20 0.43
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
PPARG P37231 1/20 0.43
SGK1 O00141 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835136 1.00 UTS2R (0.84) UTS2RMCHR1ALDH1A1LMNAERBB2
Hydrochloric Acid SCHEMBL5841999 0.93 UTS2R (0.82) UTS2RMCHR1ALDH1A1LMNAERBB2
Hydrochloric Acid SCHEMBL5841993 0.93 UTS2R (0.82) UTS2RMCHR1ALDH1A1LMNAERBB2
SCHEMBL5835212 0.92 UTS2R (0.84) UTS2RLMNAERBB2EPHA2KDR
SCHEMBL5835209 0.92 UTS2R (0.84) UTS2RLMNAERBB2EPHA2KDR
SCHEMBL5835527 0.92 UTS2R (0.81) UTS2RMCHR1ERBB2EPHA2KDR
SCHEMBL5835523 0.92 UTS2R (0.81) UTS2RMCHR1ERBB2EPHA2KDR
SCHEMBL5834848 0.92 UTS2R (0.72) UTS2RMCHR1ALDH1A1LMNAERBB2
SCHEMBL5834843 0.92 UTS2R (0.72) UTS2RMCHR1ALDH1A1LMNAERBB2
SCHEMBL5835393 0.91 UTS2R (1.00) UTS2RERBB2EPHA2KDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885MCHR1 3777/4885ALDH1A1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.